Previous 10 | Next 10 |
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial ACI-24.060 elicited an anti-Abeta antibody response in ABATE’s first, low dose cohort ACI-24.060 was general...
AC Immune Partner Life Molecular Imaging Initiates Phase 3 S tudy of Tau PET Diagnostic PI - 2620 for Alzheimer’s Disease First Alzheimer’s patient imaged with PI-2620 in A D vance , the pivotal Phase 3 ...
Summary I explain why I've added Organigram to my tax loss selling basket. I also review the company's performance and risks. Finally, I recap my entire 2022 tax loss selling basket of stocks, some of which I didn't have time to write up individually. Tax Loss Selling Strategy...
Summary ACIU has recently fallen due to what looks like indiscriminate tax loss selling. It now trades at near cash on hand and yet it has numerous programs in clinic and prestigious partners. I have added the name to my tax loss basket but may also buy additional shares for a longe...
AC Immune ’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 S elect ed for Further Development Data presented at CTAD 2022 confirm excellent clinical performance of ACI-35.030 vaccine candidate Based on this new clinical data, ACI-35.030...
Next generation SupraAntigen ® liposomal vaccine platform augments immunization against pathological targets of Alzheimer’s disease New data on anti-phospho-Tau vaccines confirm safety, tolerability and immunogenicity of ACI-35 and JACI-35, developed in collaboration w...
AC Immune press release ( NASDAQ: ACIU ): Q3 Non-GAAP EPS of -CHF0.16. Revenue of CHF3.93M. For further details see: AC Immune Non-GAAP EPS of -CHF0.16, revenue of CHF3.93M
Announced initiation of dosing of anti-Abeta vaccine ACI-24.060 in the biomarker-based Phase 1b/2 ABATE study in patients with prodromal Alzheimer’s disease and individuals with Down syndrome Received regulatory clearance to initiate an adaptive, biomarker-based Phase 2 stu...
Interim analysis expected around year-end 2022, informing Phase 2 start Trial progressing with regulatory clearances in the UK and also now in Spain Planned submission of U.S. Investigational New Drug application in Q1 2023 Continues progress towards prevention of neurodegen...
AC Immune’s Tau PET tracer moves closer to becoming a next generation diagnostic for Alzheimer’s Disease (AD) AC Immune to receive a milestone payment from LMI for progress into late-stage product development LAUSANNE, Switzerland, Sept. 26, 2022 (GLOBE NEWSWIRE) -...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...